

# Sustainability Data Content Index 2024



# Contents

SASB Index	3
GRI Content Index	6
Site certifications	10

**Online resources:**

Annual Report 2024: describes how sustainability is integrated into our business model and management of material sustainability topics.

AstraZeneca Sustainability Data Annex: provides performance measures and targets with at least three years of data, where available.

Resources page: contains additional sustainability resources including our policies and standards, Sustainability Data Reporting Criteria and Greenhouse Gas Reporting Methodology.



# SASB Index

## SASB Standard: Biotechnology & Pharmaceuticals

This is an index to the location of our disclosures that align with the Sustainability Accounting Standards Board (SASB) standard for Biotechnology & Pharmaceuticals, version 2023-12. The report provides data from 1 January 2024 to 31 December 2024, unless otherwise stated.

Metric Code	Metric	Disclosure Location
<b>Safety of Clinical Trial Participants</b>		
HC-BP-210a.1	Discussion, by region, of management process for ensuring quality and patient safety during clinical trials	Annual Report 2024, p. 38 <a href="#">Bioethics Policy</a>
HC-BP-210a.2	Number of inspections related to clinical trial management and pharmacovigilance that resulted in: (1) entity voluntary remediation or (2) regulatory or administrative actions taken against the entity	Annual Report 2024, p. 38
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto.
<b>Access to Medicines</b>		
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	Annual Report 2024, p. 52 <a href="#">2024 Access to Medicines Index Report Card</a>
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	<a href="#">WHO PreQualification approved products</a>

Metric Code	Metric	Disclosure Location
<b>Affordability &amp; Pricing</b>		
HC-BP-240b.2	Percentage change in: (1) weighted average list price and (2) weighted average net price across product portfolio compared to previous reporting period	Not Reported
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous reporting period	Not Reported
<b>Drug Safety</b>		
HC-BP-250a.1	Products listed in public medical product safety or adverse event alert databases	Annual Report 2024, p. 38 <a href="#">FDA Adverse Event Reporting</a>
HC-BP-250a.2	Number of fatalities associated with products	Not Reported
HC-BP-250a.3	(1) Number of recalls issued, (2) total units recalled	Annual Report 2024, p. 38
HC-BP-250a.4	Total amount of product accepted for take-back, reuse, or disposal	Not Reported
HC-BP-250a.5	Number of enforcement actions taken in response to violations of good manufacturing practices (GMP) or equivalent standards, by type	Annual Report 2024, p. 38
<b>Counterfeit Drugs</b>		
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	<a href="#">SASB response: Counterfeit drugs</a>
HC-BP-260a.2	Discussion of process for alerting customers and business partners to potential or known risks associated with counterfeit products	<a href="#">SASB response: Counterfeit drugs</a>
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, or filing of criminal charges related to counterfeit products	Not Reported

Metric Code	Metric	Disclosure Location
<b>Ethical Marketing</b>		
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto.
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	<a href="#">AstraZeneca Global Standard: Promoting our products</a>
<b>Employee Recruitment, Development &amp; Retention</b>		
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development staff	Annual Report 2024, pp. 49-50
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	Annual Report 2024, p. 49 Sustainability Data Annex 2024, p. 11
<b>Supply Chain Management</b>		
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit programme or equivalent third-party audit programmes for integrity of supply chain and ingredients	We do not use third-party auditing organisations. AstraZeneca has an internal risk based supplier assessment system. In 2024 Global Quality Audit completed 449 internal quality audits of AstraZeneca suppliers and 53 internal quality audits of AstraZeneca sites. Sustainability Data Annex 2024, p. 12
<b>Business Ethics</b>		
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	To the extent we are aware of any material responsive matters, they would have been disclosed as part of our Annual Reports and Form 20-F Information, and quarterly updates thereto.
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	<a href="#">AstraZeneca and Global Transparency</a>
<b>Activity Metrics</b>		
HC-BP-000.A	Number of patients treated	Annual Report 2024, p. 10
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	<a href="#">Our medicines</a> <a href="#">Development Pipeline</a> as at 6 February 2025

# GRI Content Index

## Statement of use

AstraZeneca has reported in accordance with the GRI Standards for the period 1 January 2024 - 31 December 2024.

## GRI 1 used

GRI 1: Foundation 2021

GRI Standard	Disclosure	Location
<b>General Disclosures</b>		
GRI 2: General Disclosures 2021	2-1 Organizational details	Annual Report 2024, pp. IFC, 214-218, 221, 228, 231
	2-2 Entities included in the organization's sustainability reporting	The reporting covers AstraZeneca Group, unless otherwise stated. Annual Report 2024, pp. IFC, 214-218. Greenhouse Gas Reporting Methodology 2024, p. 2
	2-3 Reporting period, frequency and contact point	AstraZeneca publishes an annual report annually. The GRI Content Index was released on 18 February 2025 and covers the reporting period 1 January 2024 to 31 December 2024. Questions about the report or reported information can be sent to <a href="mailto:disclosures@astrazeneca.com">disclosures@astrazeneca.com</a>
	2-4 Restatements of information	Annual Report 2024, p. 233 Sustainability Data Reporting Criteria 2024, p. 2 Greenhouse Gas Reporting Methodology 2024, p. 9
	2-5 External assurance	Annual Report 2024, pp. 51, 233 <a href="#">Letter of Assurance</a>
	2-6 Activities, value chain and other business relationships	Annual Report 2024, pp. 10-11, 43
	2-7 Employees	Annual Report 2024, pp. 33, 48
	2-8 Workers who are not employees	Not reported
	2-9 Governance structure and composition	Annual Report 2024, pp. 87-89, 100-101
	2-10 Nomination and selection of the highest governance body	Annual Report 2024, pp. 100-101
	2-11 Chair of the highest governance body	Annual Report 2024, pp. 88-89
	2-12 Role of the highest governance body in overseeing the management of impacts	Annual Report 2024, pp. 51, 91-93, 103, 104 <a href="#">Terms of Reference of the AstraZeneca Sustainability Committee</a>

**GRI Standard****Disclosure****Location****General Disclosures**

GRI 2: General Disclosures 2021	2-13 Delegation of responsibility for managing impacts	Annual Report 2024, p. 51
	2-14 Role of the highest governance body in sustainability reporting	Annual Report 2024, pp. 51, 103, 104-106 <a href="#">Terms of Reference of the AstraZeneca Sustainability Committee</a> <a href="#">Terms of Reference of the AstraZeneca Audit Committee</a>
	2-15 Conflicts of interest	Annual Report 2024, p. 228
	2-16 Communication of critical concerns	Annual Report 2024, pp. 42-43, 93
	2-17 Collective knowledge of the highest governance body	Annual Report 2024, pp. 100-101, 103
	2-18 Evaluation of the performance of the highest governance body	Annual Report 2024, p. 99
	2-19 Remuneration policies	Annual Report 2024, pp. 93, 112-136 <a href="#">Remuneration Policy</a>
	2-20 Process to determine remuneration	Annual Report 2024, pp. 93, 112-136 <a href="#">Remuneration Policy</a>
	2-21 Annual total compensation ratio	Annual Report 2024, p. 133
	2-22 Statement on sustainable development strategy	Annual Report 2024, pp. 2-4
	2-23 Policy commitments	Annual Report 2024, pp. 42-43 <a href="#">Code of Ethics</a> <a href="#">Human Rights Statement</a>
	2-24 Embedding policy commitments	<a href="#">Expectations of Third Parties</a> <a href="#">Code of Ethics</a> <a href="#">Human Rights Statement</a>
	2-25 Processes to remediate negative impacts	<a href="#">Expectations of Third Parties</a> <a href="#">Code of Ethics</a> <a href="#">Human Rights Statement</a>
	2-26 Mechanisms for seeking advice and raising concerns	Annual Report 2024, pp. 42-43
	2-27 Compliance with laws and regulations	Annual Report 2024, pp. 204-211 Sustainability Data Annex 2024, p. 8
	2-28 Membership associations	Annual Report 2024, pp. 38, 52, 58 <a href="#">Partnerships, alliances and recognition</a>
	2-29 Approach to stakeholder engagement	Annual Report 2024, pp. 50, 60, 94-96, 98
	2-30 Collective bargaining agreements	Annual Report 2024, p. 50

GRI Standard	Disclosure	Location
<b>Material topics</b>		
GRI 3: Material Topics 2021	3-1 Process to determine material topics	Annual Report 2024, pp. 60, 94-96
	3-2 List of material topics	Annual Report 2024, pp. 32, 60
<b>Sustainable innovation</b>		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2024, pp. 37, 94-96
AstraZeneca specific disclosures	Number of new molecular entities (NMEs) approvals (cumulative)	Annual Report 2024, pp. 13, 234
	Number of pipeline progression events	Annual Report 2024, pp. 13, 234
	Number of regulatory events	Annual Report 2024, pp. 13, 234
<b>Patient safety and product quality</b>		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2024, pp. 38, 94-96
AstraZeneca specific disclosures	Number of inspections from health authorities relating to Good Manufacturing Practice	Annual Report 2024, pp. 38, 234
	Number of critical findings from health authorities relating to Good Manufacturing Practice	Annual Report 2024, pp. 38, 234
	Number of product recalls	Annual Report 2024, pp. 38, 234
<b>Business conduct</b>		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2024, pp. 42-43, 94-96
<b>Cybersecurity and data privacy</b>		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2024, pp. 45, 94-96
AstraZeneca specific disclosures	Number of material cybersecurity incidents	Annual Report 2024, pp. 45, 234
	Number of material security breaches involving personal data	Annual Report 2024, pp. 45, 234



<b>GRI Standard</b>	<b>Disclosure</b>	<b>Location</b>
<b>Talent attraction and retention</b>		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2024, pp. 49-50, 94-96
AstraZeneca specific disclosures	Employee belief that in the last 12 months, I have improved my existing skills, or learned new skills, or had a development opportunity	Annual Report 2024, pp. 49, 235
	Employee belief that AstraZeneca is a great place to work	Annual Report 2024, pp. 49, 235
	Employee overall promotion rate	Annual Report 2024, pp. 49, 235
	Employee turnover	Annual Report 2024, pp. 49, 235
<b>Accessible and affordable healthcare</b>		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2024, pp. 52, 94-96
<b>Climate change</b>		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2024, pp. 53-57, 94-96
GRI 201: Economic performance 2016	201-2 Financial implications and other risks and opportunities due to climate change	Annual Report 2024, pp. 55-57, 64
GRI 305: Emissions 2016	305-1 Direct (Scope 1) GHG emissions	Annual Report 2024, pp. 53, 235
	305-2 Energy indirect (Scope 2) GHG emissions	Annual Report 2024, pp. 53, 235
	305-3 Other indirect (Scope 3) GHG emissions	Annual Report 2024, pp. 53, 235
	305-4 GHG emissions intensity	Annual Report 2024, pp. 53, 235
<b>Pollution</b>		
GRI 3: Material Topics 2021	3-3 Management of material topics	Annual Report 2024, pp. 58, 94-96

# Site certifications

June 2024

## 77%

Share of R&D and Operations sites with environmental certifications (ISO 14001, ISO 50001, or My Green Lab).

## 6%

Share of sites with sustainable building certifications (LEED, BREEAM or WELL).

## 10%

Share of R&D and Operations sites with certified occupational health and safety management systems (ISO 45001).

